Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Bile acid receptor79 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00022 | 35251469 | Oxid Med Cell Longev | Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. | 2022 | Details |
| A00107 | 35217817 | Acta Pharmacol Sin | Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. | 2022 | Details |
| A00474 | 35068796 | J Clin Exp Hepatol | A Current Understanding of Bile Acids in Chronic Liver Disease. | 2021 | Details |
| A00655 | 35013582 | Sci Rep | PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice. | 2022 | Details |
| A00700 | 34998040 | Eur J Med Chem | Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis. | 2021 | Details |
| A00797 | 34964117 | Compr Physiol | Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. | 2021 | Details |
| A01195 | 34831031 | Cells | Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01402 | 34759011 | Drug Metab Dispos | Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling. | 2021 | Details |
| A02213 | 34458376 | J Immunol Res | Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway. | 2021 | Details |
| A02796 | 34236487 | Semin Immunopathol | Role of bile acids in inflammatory liver diseases. | 2021 | Details |
| A04114 | 33752128 | EBioMedicine | Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis. | 2021 | Details |
| A04243 | 33692776 | Front Immunol | TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation. | 2021 | Details |
| A04783 | 33506572 | Liver Int | Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease. | 2021 | Details |
| A05346 | 33292701 | Biomark Res | Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function. | 2020 | Details |
| A05479 | 33242590 | Biochim Biophys Acta Mol Basis Dis | Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy. | 2020 | Details |
| A06866 | 32717871 | Int J Mol Sci | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. | 2020 | Details |
| A07297 | 32552182 | Expert Opin Investig Drugs | Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). | 2020 | Details |
| A07424 | 32505776 | Clin Chim Acta | Intestinal microbiota-farnesoid X receptor axis in metabolic diseases. | 2020 | Details |
| A07880 | 32325178 | J Ethnopharmacol | Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. | 2020 | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | 2020 | Details |
| A09057 | 34350368 | Cardiol Plus | Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy. | 2020 | Details |
| A09195 | 31840358 | Hepatol Res | Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. | 2020 | Details |
| A10427 | 31341422 | Mediators Inflamm | Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10456 | 31330134 | Metabolism | AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. | 2019 | Details |
| A10928 | 31117231 | Nutrients | Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. | 2019 | Details |
| A10986 | 31090267 | J Zhejiang Univ Sci B | Bile-ology: from bench to bedside. | 2019 | Details |
| A11679 | 30792450 | Sci Rep | Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1. | 2019 | Details |
| A12145 | 30582898 | Biochem Pharmacol | Developments in bile salt based therapies: A critical overview. | 2018 | Details |
| A12750 | 30303744 | FASEB J | Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. | 2018 | Details |
| A13187 | 30095299 | Am J Physiol Gastrointest Liver Physiol | High-fat diet overfeeding promotes nondetrimental liver steatosis in female mice. | 2018 | Details |
| A13504 | 29945982 | J Endocrinol | INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function. | 2018 | Details |
| A13710 | 29797516 | Eur J Clin Invest | Exercising the hepatobiliary-gut axis. The impact of physical activity performance. | 2018 | Details |
| A14541 | 29361497 | Mol Metab | Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. | 2018 | Details |
| A14699 | 29285942 | Orv Hetil | [Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases]. | 2017 | Details |
| A15083 | 29104811 | Liver Res | Bile acid metabolism and signaling in liver disease and therapy. | 2017 | Details |
| A15097 | 29098111 | Liver Res | Bile acid receptors link nutrient sensing to metabolic regulation. | 2017 | Details |
| A16681 | 28249273 | Dig Dis | Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation. | 2017 | Details |
| A16919 | 28092182 | Exp Biol Med (Maywood) | An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors. | 2017 | Details |
| A17923 | 27475255 | Biochim Biophys Acta | Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice. | 2016 | Details |
| A18082 | 27358174 | Hepatology | Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. | 2016 | Details |
| A18919 | 26870934 | Semin Liver Dis | Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A19259 | 26668692 | World J Hepatol | Bile acid receptors and nonalcoholic fatty liver disease. | 2015 | Details |
| A19282 | 26655953 | J Biol Chem | Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice. | 2015 | Details |
| A19419 | 26579441 | Acta Pharm Sin B | Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. | 2015 | Details |
| A20094 | 26159280 | Dig Dis | Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. | 2015 | Details |
| A20845 | 25690590 | Curr Atheroscler Rep | FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. | 2015 | Details |
| A22830 | 24275855 | Curr Opin Oncol | Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. | 2014 | Details |
| A23168 | 23988487 | Biochem Pharmacol | Bile acid receptors in non-alcoholic fatty liver disease. | 2013 | Details |
| A23805 | 23460643 | J Biol Chem | Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. | 2013 | Details |
| A26226 | 20868235 | Biol Chem | Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. | 2010 | Details |
| A29086 | 34603061 | Front Pharmacol | Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. | 2021 | Details |
| A30489 | 32355675 | Hepatobiliary Surg Nutr | Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. | 2020 | Details |
| A31125 | 31201554 | Handb Exp Pharmacol | Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists. | 2019 | Details |
| A31690 | 30034914 | Liver Res | Bile acid signaling and bariatric surgery. | 2017 | Details |
| A31747 | 29933033 | Pharmacol Ther | Progress and challenges of selective Farnesoid X Receptor modulation. | 2018 | Details |
| A31765 | 29900399 | Data Brief | The effect of synbiotics Bifidobacterium infantis and milk oligosaccharides on shaping gut microbiota community structure and NASH treatment. | 2018 | Details |
| A42477 | 34436472 | Metabolites | The Role of Gut Microbiota and Its Produced Metabolites in Obesity, Dyslipidemia, Adipocyte Dysfunction, and Its Interventions. | 2021 | Details |
| A43319 | 31984784 | Am J Physiol Gastrointest Liver Physiol | Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. | 2020 | Details |
| A44127 | 29651702 | Hepatol Int | Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation. | 2018 | Details |
| A44774 | 27351453 | Hepatology | G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. | 2016 | Details |
| A44775 | 27347902 | Compr Physiol | Functions of the Gallbladder. | 2016 | Details |
| A45353 | 25073467 | Pharmacol Rev | Bile acid signaling in metabolic disease and drug therapy. | 2014 | Details |
| A46907 | 34896286 | Cell Mol Gastroenterol Hepatol | Bile Acid-Mediated Activation of Brown Fat Protects From Alcohol-Induced Steatosis and Liver Injury in Mice. | 2021 | Details |
| A47823 | 31302759 | Handb Exp Pharmacol | Bile Acid-Activated Receptors: GPBAR1 (TGR5) and Other G Protein-Coupled Receptors. | 2019 | Details |
| A47881 | 30141927 | J Med Chem | Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5). | 2018 | Details |
| A48660 | 32064266 | Front Med (Lausanne) | Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases. | 2020 | Details |
| A48662 | 32039388 | JHEP Rep | Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis. | 2019 | Details |
| A48732 | 30353976 | ChemMedChem | Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators. | 2018 | Details |
| A48743 | 30026040 | Bioorg Med Chem | Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists. | 2018 | Details |
| A48819 | 27639537 | Lancet Diabetes Endocrinol | Clinical relevance of the bile acid receptor TGR5 in metabolism. | 2016 | Details |
| A48840 | 26824277 | Future Med Chem | SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound. | 2016 | Details |
| A49894 | 35605722 | Mol Cell Endocrinol | Recent advances on FXR-targeting therapeutics. | 2022 | Details |
| A49895 | 35605662 | J Biol Chem | Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. | 2022 | Details |
| A50026 | 35559268 | Front Pharmacol | Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease. | 2022 | Details |
| A50737 | 35283218 | Mol Cell Endocrinol | Discovery of farnesoid X receptor and its role in bile acid metabolism. | 2022 | Details |
| A50758 | 35276916 | Nutrients | A Lard and Soybean Oil Mixture Alleviates Low-Fat-High-Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. | 2022 | Details |
| A52009 | 32359213 | Mol Nutr Food Res | Novel Strategies to Prevent Total Parenteral Nutrition-Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes. | 2020 | Details |
| A52445 | 27067456 | J Hepatol | A synthetic biology-based device prevents liver injury in mice. | 2016 | Details |
| A52863 | 20512997 | Hepatology | Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. | 2010 | Details |